Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research report issued on Tuesday, AnalystRatings.com reports. They presently have a $30.00 price objective on the stock. Mizuho’s price target suggests a potential upside of 205.19% from the stock’s current price.

Several other equities analysts have also commented on EOLS. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, November 4th. Zacks Investment Research upgraded shares of Evolus from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. Leerink Swann initiated coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective on the stock. Svb Leerink began coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Evolus in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $26.36.

Shares of EOLS stock traded down $0.27 during trading hours on Tuesday, hitting $9.83. The company had a trading volume of 338,848 shares, compared to its average volume of 660,470. The company’s fifty day moving average is $11.79 and its 200 day moving average is $14.81. The company has a debt-to-equity ratio of 4.53, a current ratio of 3.66 and a quick ratio of 3.28. Evolus has a fifty-two week low of $10.00 and a fifty-two week high of $30.25. The stock has a market capitalization of $373.02 million, a PE ratio of -3.06 and a beta of 4.24.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.55. The company had revenue of $13.17 million during the quarter, compared to analyst estimates of $5.18 million. Equities analysts forecast that Evolus will post -3.75 earnings per share for the current year.

In related news, insider Rui Avelar sold 39,442 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.71, for a total transaction of $422,423.82. Following the sale, the insider now directly owns 70,802 shares of the company’s stock, valued at approximately $758,289.42. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp increased its position in shares of Evolus by 21.6% in the 3rd quarter. State Street Corp now owns 230,987 shares of the company’s stock valued at $3,608,000 after purchasing an additional 41,046 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in Evolus during the second quarter valued at approximately $4,167,000. Rhumbline Advisers lifted its position in Evolus by 15.2% during the third quarter. Rhumbline Advisers now owns 14,797 shares of the company’s stock valued at $231,000 after buying an additional 1,953 shares in the last quarter. Millennium Management LLC raised its stake in shares of Evolus by 36.7% during the third quarter. Millennium Management LLC now owns 170,072 shares of the company’s stock valued at $2,656,000 after purchasing an additional 45,653 shares during the period. Finally, HighTower Advisors LLC purchased a new stake in shares of Evolus during the second quarter valued at approximately $175,000. 16.94% of the stock is currently owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading: What is a resistance level?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.